本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ascendis Pharma A/S

216.32
-1.7800-0.82%
盤後216.320.00000.00%17:21 EST
成交量:69.88萬
成交額:1.52億
市值:133.46億
市盈率:-47.66
高:221.80
開:217.85
低:213.02
收:218.10
52周最高:242.00
52周最低:124.06
股本:6,169.52萬
流通股本:6,008.34萬
量比:0.69
換手率:1.16%
股息:- -
股息率:- -
每股收益(TTM):-4.5384
每股收益(LYR):-6.7615
淨資產收益率:-818.43%
總資產收益率:-6.86%
市淨率:-69.04
市盈率(LYR):-31.99

資料載入中...

公司資料

公司名字:
Ascendis Pharma A/S
交易所:
NASDAQ
成立時間:
2006
員工人數:
1017
公司地址:
Tuborg Boulevard 12,Hellerup,Capital Region of Denmark,Denmark
郵編:
2900
傳真:
- -
簡介:
Ascendis Pharma A/s成立於2006年9月21日。該公司是一家臨床階段的生物製藥公司,該公司運用其TransCon技術開發具有最佳的長效藥物療法的管道以解決大市場顯著未滿足的醫療需求。該公司正在開發其先導候選產品,TransCon人生長激素或生長激素TransCon,每周一次給藥治療生長激素缺乏症以及其他疾病。

董事

名稱
職位
Albert Cha
Chairman of the Board and Director
Jan Moller Mikkelsen
Chief Executive Officer and Director and President
Lars Holtug
Director
Lisa Bright
Director
Siham Imani
Director
William Carl Fairey Jr.
Director

股東

名稱
職位
Jan Moller Mikkelsen
Chief Executive Officer and Director and President
Mads Bodenhoff
Head of Finance and Principal Accounting Officer and Senior Vice President
Scott T. Smith
Executive Vice President, Chief Financial Officer
Aimee Shu
Executive Vice President, Chief Medical Officer
Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Jay Donovan Wu
Executive Vice President, U.S. President
Jethro Ekuta
Chief Regulatory & Safety Officer
Kennett Sprogøe
Executive Vice President, Head of Innovation and Research
Lotte Sonderbjerg
Executive Vice President, Chief Administrative Officer
Michael Wolff Jensen
Executive Vice President, Chief Legal Officer
Sherrie Glass
Chief Business Officer
Stina Singel
Executive Vice President, Head of Clinical Development, Oncology